Keifei Pharma | Retatrutide 60mg (Retatrutifei – 3 × 20mg Vials) | Compound Peptide Vial
Advanced Triple Receptor Metabolic Research Compound
Keifei Pharma Retatrutifei 60mg is an investigational peptide research compound studied for its multi-receptor activity across GLP-1, GIP, and glucagon pathways, widely referenced in laboratory research exploring complex metabolic regulation, energy balance mechanisms, and endocrine signalling interactions.
Triple agonist compounds are commonly investigated in scientific models focused on glucose metabolism, appetite regulation pathways, and multi-system hormonal communication within controlled experimental environments.
Developed as a 60mg total pack (3 × 20mg vials), this formulation is designed for laboratory preparation and controlled research applications where multi-pathway metabolic signalling and receptor interaction studies are of scientific interest.
Keifei Pharma Retatrutifei 60mg Compound Peptide Vial (3 × 20mg)
• Triple receptor research compound (GLP-1, GIP, glucagon pathways)
• Investigated in metabolic signalling and endocrine regulation models
• Of interest in glucose homeostasis and energy balance research
• Explored in multi-pathway hormonal interaction studies
• 3 × 20mg vial format designed for laboratory preparation use
• High-purity investigational formulation from Keifei Pharma
• Manufactured for stability, consistency, and research reliability
• Strictly intended for laboratory research use only
⚖️ DISCLAIMER
This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPHRA) for human or animal use.
This product is supplied strictly for laboratory research purposes only and is not intended for human consumption.
